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The perception of reactive oxygen species has evolved over the past decade from
agents of cellular damage to secondary messengers which modify signaling proteins in
physiology and the disease state (e.g., cancer). New protein targets of speciﬁc oxidation
are rapidly being identiﬁed. One emerging class of redox modiﬁcation occurs to the thiol
side chain of cysteine residues which can produce multiple chemically distinct alterations
to the protein (e.g., sulfenic/sulﬁnic/sulfonic acid, disulﬁdes). These post-translational
modiﬁcations (PTM) are shown to affect the protein structure and function. Because
redox-sensitive proteins can trafﬁc between subcellular compartments that have different
redox environments, cysteine oxidation enables a spatio-temporal control to signaling.
Understanding ramiﬁcations of these oxidative modiﬁcations to the functions of signaling
proteins is crucial for understanding cellular regulation as well as for informed-drug
discovery process. The effects of EGFR oxidation of Cys797 on inhibitor pharmacology are
presented to illustrate the principle. Taken together, cysteine redox PTM can impact both
cell biology and drug pharmacology.
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INTRODUCTION
Reactive oxygen species (ROS) are the product of tightly controlled
metabolic and cellular processes including mitochondrial respira-
tion, cytokine and mitogen stimulations. They are also produced
in response to external stressors such as pathogens, chemi-
cals, and radiation (Bae et al., 1997; Dickinson and Chang, 2011;
Bindoli and Rigobello, 2013). The ROS family broadly encom-
passes free radical (e.g., superoxide, ·O−2 ; hydroxyl, ·OH) and
non-radical (e.g., peroxides) species (Cross and Templeton,
2006; Jacob et al., 2011). Superoxides and hydrogen peroxide
are kinetically favorable for modifying select cysteine residues
due to their regulated production (enzymatic, non-enzymatic),
different rates of formation, half-lives and inherent reactivi-
ties relative to the more “toxic” hydroxyl radical (D’Autreaux
and Toledano, 2007; Winterbourn, 2008; Drose and Brandt,
2012; Marinho et al., 2014). The key determinants of whether
ROS function as secondary messengers for signal transduc-
tion or agents of cellular damage reside in the amount, type
and cellular location of reactive species produced in response
to its molecular trigger. Commonly understood aspects of
redox modiﬁcations from ROS exposure include changes to
the structure and conformation of proteins as well as inac-
tivation of catalytic residues. However, the ability of speciﬁc
oxidation reactions with ROS to alter interactions with small
molecule inhibitors is poorly understood. The goal of this
Perspective is to illuminate the complex interplay of local-
ized production of ROS, protein oxidation events and drug
interactions.
THE CHEMISTRY OF CYSTEINE BIOLOGY: WHY CELLS PREFER
CYSTEINE FOR OXIDATION?
The knowledge of sulfur chemistry is central to understanding
how and why cysteine residues get preferentially oxidized dur-
ing biological regulation. There are two sulfur-containing residues
in the mammalian proteome, cysteine and methionine, of which
cysteine constitutes 1–2% (Miseta and Csutora, 2000). The facile
chemistry of cysteine stems from the electronic structure of its
thiol group which enables multiple oxidation states (from −2
to +6) leading to an array of redox modiﬁcations (sulfenylation,
SOH; sulﬁnylation, SO2H; sulﬁnylation, SO3H; glutathionylation,
-SSG; protein disulﬁde formation; nitrosylation, etc.) with distinct
chemical properties that contribute to signaling speciﬁcity (Wang
et al., 2012). For instance, oxidation of the relatively hydrophobic
cysteine residue to an oxoacid form (e.g., sulﬁnic acid) funda-
mentally changes it to a highly polar residue. Also, many types
of cysteine oxidative modiﬁcations are readily reversible making
them well-suited for initiating, amplifying, and terminating redox
signaling relative to other residues (Bindoli et al., 2008). As such,
this malleable chemistry confers unique capabilities to cysteine
residues for sensing and transducing signaling by modifying the
structure and function of proteins.
Oxidation of methionine, the other sulfur-containing amino
acid, also leads to similar chemotypes as cysteine, however;
the slower rate of methionine oxidation combined with rapid
reduction by methionine sulfoxide reductase (MSR) minimizes
its role in signaling regulation and suggests a role as redox
scavengers (D’Autreaux and Toledano, 2007). Furthermore,
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reduced MSR expression in cells, aging individuals, andAlzheimer
subjects is correlated with increased methionine oxidation
which is consistent with an antioxidant function (Moskovitz,
2005; Schoneich, 2005; Moskovitz et al., 2011; Ringman et al.,
2012). However, a recent study infers a role of methion-
ine oxidation in signaling due to its proximity to Ser/Thr/Tyr
residues which could impact phosphorylation networks (Rao
et al., 2013). Further research on this intriguing correlation is
necessary to establish the role of methionine oxidation as a
signaling regulator. In addition to the sulfur-containing amino
acids, oxidation of other amino acid residues can occur but
they are not readily reversible making them ill-suited for ini-
tiating rapid on/off responses to upstream signals (Dickin-
son and Chang, 2011; Corcoran and Cotter, 2013). Cysteine
oxidative modiﬁcations are therefore preferred for modulat-
ing signal transduction since they readily react with most ROS
(Schoneich, 2011) to create a range of modiﬁcations that are
largely reversible.
With an increased array of selective probes that label dif-
ferent redox chemotypes, our knowledge of proteins mod-
iﬁed by oxidation is growing rapidly. Some of the known
redox-modiﬁed kinases include MKK4 (Diao et al., 2010), PKC
(protein kinase C) (Gopalakrishna and Jaken, 2000; Korich-
neva, 2005), Src (sarcoma kinase) (Giannoni et al., 2005),
Akt2 (Wani et al., 2011), and more recently EGFR (epider-
mal growth factor receptor) (Paulsen et al., 2012; Schwartz
et al., 2014). These modiﬁcations can be activating (PKC, Src,
EGFR) or inhibitory (MKK4, AKT2). Redox-inactivation of
phosphatases such as PTP1B, PTEN, and PP2A is also well-
characterized (Kwon et al., 2004; Foley et al., 2007; Östman
et al., 2011; Kitagishi and Matsuda, 2013). Other protein classes
are also oxidatively modiﬁed including transcription factors
(Surh et al., 2005; Cross and Templeton, 2006), ion channels;
mitochondrial transporter proteins (O-Uchi et al., 2014), and
cytoskeletal proteins (Landino et al., 2007; Farah et al., 2011).
Therefore, selective oxidation of cysteine residues are post-
translational modiﬁcations (PTM) with unique properties and
capabilities.
COMPARTMENTALIZED SIGNALING CONTRIBUTES TO
SPECIFICITY OF REDOX REGULATION
Ligand stimulation of receptor tyrosine kinases (RTK) causes
the translocation of the ligand – RTK complexes to clathrin-
coated pits on the plasma membrane which bud off as endo-
somes and internalize (Carpenter and Liao, 2009; Murphy
et al., 2009). From the endosome, RTK’s can trafﬁck to lyso-
somes for degradation, to other intracellular destinations (e.g.,
cytoplasm, nucleus, mitochondria), or back to the membrane
(recycling). EGFR endocytosis is a fairly well-understood pro-
cess which also enables signaling from the endosome itself.
(Paige Davis Volk and Moreland, 2014). Depending on the type
of ligand (e.g., EGF, TGFα) and its dimerization partner, EGFR
trafﬁcking can either terminate in the lysosomes (following EGFR-
ubiquitination) or at the membrane (recycling; Murphy et al.,
2009; Sorkin and Goh, 2009). The mechanism of spatial regu-
lation of EGFR signaling can be inferred from empirical studies
that demonstrate how endoplasmic reticulum (ER)-based NOX4
produces ROS to locally inactivate the phosphatase PTP1B which
allows the active receptor (phosphorylated EGFR) to recycle back
to the membrane (Chen et al., 2008; Tomas et al., 2014). This
diffusion-restricted process promotes spatial RTK signaling by
(1) localizing ROS within the endosomal compartment and (2)
preventing plasma membrane and cytoplasmic regulators (e.g.,
glutathione, antioxidant enzymes, trace metals) from interacting
with the endosomal ROS. As such, the endosomal environment
alters the local half-life of select ROS species to impart signaling
selectivity.
Different oxidative modiﬁcations of the same protein, but
at distinct subcellular locations, can add another layer of com-
plexity to redox regulation. For example, recent biochemical
studies on the reactivation of peroxide-inactivated PTP1B ﬁnd
different rates of recovery of its activity based on the reduction
mechanism – enzymatic (thioredoxin, Trx) or by a non-protein
thiol (glutathione, GSH). This study indicated that Trx selectively
reduces lower order redox forms (sulfenic acid and sulfenyl amide)
of PTP1B compared to GSH,which could also reduce some higher
oxidized forms or sulﬁnyl derivatives of PTP1B. Interestingly,
under comparable conditions Trx restored catalytic activity of
PTP1B more efﬁciently than GSH (Parsons and Gates, 2013). If we
extend this concept to cellular settings and assume that a fraction
of PTP1B is localized within an endosome, then the stabilization
of its sulfenyl form relative to the sulﬁnyl fraction would be largely
determined by the dominant reducing agent in an endosome
(Trx vs. GSH). Integrating this process with EGFR endocytosis
suggests that the recycling rate of PTP1B would directly regu-
late the lifetime of active EGFR and therefore the amplitude of
endosomal EGFR signaling. Also, the differential stability of indi-
vidual sulfenylated/sulﬁnylated/disulﬁde-linked fractions of the
EGFR molecules within endosomes can contribute to its signaling
regulation.
Cysteine reactivity can be context-speciﬁc because the acid dis-
sociation constant (pKa) of a cysteine residue’s thiol varies widely
in proteins (pKa 3–9) depending on many factors (Cremers and
Jakob, 2013). As redox-sensitive proteins travel between differ-
ent cellular compartments they are subjected to rapid changes
in local pH, redox environment (vicinal protein/non-protein thi-
ols, proximity to metal centers and positively charged residues)
and solvent access that collectively affect the pKa of their critical
cysteine(s) (Roos et al., 2013). Thus, the local microenvironment
affects protein thiol nucleophilicity which promotes spatially dis-
tinct, redox-mediated signaling. In addition, the different intrinsic
rates of formation, diffusibility and stability of ROS (Bindoli et al.,
2008) in these subcellular compartments adds a temporal control
to redox regulation.
Post-translational modiﬁcations other than oxidation (e.g.,
phosphorylation, glycosylation, ubiquitination) can combinewith
redox regulation to impact cellular functions. For example, recent
studies indicate that sodium arsenite-mediated oxidative stress
promotes nuclear expulsion of the transcription factor Nurr1; a
protein involved in survival of dopaminergic neurons with possi-
ble implications in neurodegenerative disorders such as Parkinson
(García-Yagüe et al., 2013). As Erk1/2 phosphorylates Nurr1 (Lu
et al., 2012), there is a possibility for combined phosphorylation
and redox regulation in the nuclear/cytoplasmic trafﬁcking of
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Nurr1. In case of EGFR, hydrogen peroxide treatment in cells
is known to induce both EGFR phosphorylation and oxidation
at Cys797 (sulfenylation; Paulsen et al., 2012) which independently
enhance its catalytic activity. Hydrogen peroxide treatment of cells
also enables trafﬁcking of active EGFR to the perinuclear region
by selective endocytosis (caveolar) and blocks ubiquitin-mediated
degradation resulting in prolonged EGFR signaling (Khan et al.,
2006; Sorkin and Goh, 2009). The narrow time window between
peroxide-driven oxidation and phosphorylation could play a role
in regulating membrane-based versus endosomal EGFR signal-
ing. Therefore, resolving the time courses of individual PTMs can
be crucial to understanding the functional responses of signaling
proteins. Taken together, dynamic variations in the redox environ-
ment, nucleophilicity of the cysteine thiol, and the interplay with
other PTMs during trafﬁcking collectively determines the stability
of a select protein oxidation event in a subcellular compartment
thus resolving the kinetics of spatio-temporal signaling.
DOES OXIDATION MODULATE PROTEIN CONFORMATION?
The structure and conformation of proteins are central to their
biological function. Redox regulation of protein conformation
can be achieved by multiple mechanisms (1) cysteine oxidation
leading to disulﬁde bond formation, (2) cysteine-dependent metal
cofactor interactions, and (3) cysteine modiﬁcations that alter the
topography of a protein (e.g., sulﬁnic acid, sulfenamide). Disul-
ﬁde bond formation is a well-established mechanism stabilizing
higher order protein structures occurring in the oxidizing envi-
ronment of ER during protein maturation (Zhong and Wright,
2013). These structural disulﬁde bonds are characterized by very
low redox potentials (as low as −470 mV; Fan et al., 2009; Wouters
et al., 2010) and will not be addressed in this Perspective. Another
category of disulﬁde bondhas emergedmore recently, redox-active
disulﬁde bonds, which are energetically distinct from structural
disulﬁdes (redox potential from −95 to −330 mV) and are used in
dynamic regulatory mechanisms (Fan et al., 2009; Wouters et al.,
2010). For example, integrins require reduced cysteine residues to
achieve an active conformation and are inactivated upon disulﬁde
bond formation (Yan and Smith, 2000, 2001; Chigaev et al., 2004).
DTT-induced reduction (in vitro) of the candidate disulﬁde bonds
(Cys406/Cys655, Cys457/Cys495) and disulﬁde rearrangements of
other cysteine residues drives the integrin conformation to its
active state. This mechanism of integrin activation has been tar-
geted by a small molecule agent to re-sensitize drug-resistant acute
myelogenous leukemia cells to chemotherapy (Layani-Bazar et al.,
2014). Another biological relevant catagory of disulﬁde bond
is mixed disulﬁdes (e.g., glutathionylation). Actin glutathiony-
lation studies illustrate the functional signiﬁcance of this type
of modiﬁcation. Ischemia-reperfusion induces glutathionylation
of actin at Cys374 which blocks polymerization of α-actin ﬁla-
ments, decreases actomyosin ATPase activity (Pizarro and Ogut,
2009), and reduces muscle contractility. An array of sarcomeric
proteins are additionally shown to be oxidized, (e.g., troponin,
tropomyosin) suggesting that cardiac contractility is regulated by
a network of redox-modiﬁed proteins (Steinberg, 2013).
Thewell-studiedmechanismof redox-induced conformational
change involves metal-derived redox reactions that occur fre-
quently with changes in cellular thiol balance (Ilbert et al., 2006;
Fan et al., 2009). Conformational changes resulting from Zn
release in proteins such as Hsp33 (Ilbert et al., 2006), metalloth-
ionein (Oteiza, 2012), thioredoxin 2 from Escherichia coli (El
Hajjaji et al., 2009), PKC (Zhao et al., 2011), and antisigma fac-
tor RsrA (Heo et al., 2013) routinely occur following oxidative
stress. The coordinating cysteine residues in the zinc ﬁnger cluster
form intramolecular disulﬁdes releasing Zn which leads to unfold-
ing of the redox-responsive region in Hsp33. This exposes both
the dimerization interface and substrate binding site to enhance
folding of the target proteins and alternatively prevents their
aggregation until the cellular stress (e.g., redox, temperature) is
relieved (Ilbert et al., 2006). Kinetic studies measuring reactiv-
ities of zinc ﬁnger peptides with peroxide and oxygen suggest
that binding of Zn to the reduced Hsp33 monomers minimizes
the nucleophilicity or thiolate form (S-) of the coordinating cys-
teine residues and curbs redox reactions (Bourles et al., 2011).
Another example is the zincmetalloproteinmetallothioneinwhich
is redox-regulated to affect zinc transfer and homeostasis (Oteiza,
2012).
Speciﬁc redox modiﬁcations of cysteine residues can change
their chemical properties, alter protein topography, and con-
tribute to biological regulation. For example, oxidation of PTP-1B
catalytic cysteine (Cys215) to sulfenamide via a sulfenic acid inter-
mediate induces major structural rearrangements of two loops
in its active site and is shown to be essential for substrate
recognition and catalysis (Brandes et al., 2009). Taken together,
redox-regulated conformational changes in signaling proteins
occur by an array of mechanisms and play important roles in
biological regulation.
ONCOLOGY TARGETS OF REDOX: KINASES WITH A HINGE
REGION CYSTEINE IN THEIR CATALYTIC DOMAIN
One of the best known non-catalytic cysteine nucleophiles occurs
in the catalytic domain of a group of 11 protein kinases that
includes EGFR. A brief overview of the known pathophysiolog-
ical roles of these kinases along with a list of investigational
and approved drugs from the most recent literature is included
(Table 1). In physiological conditions, EGF ligand stimulation
induces receptor dimerization followed by autophosphorylation
of activation loop tyrosine residues, recruitment of the adap-
tor proteins, and activation of downstream signaling pathways
to regulate fundamental cellular processes. In the disease set-
ting, EGFR can be up-regulated, mutated, and constitutively
activated in a range of solid tumors and leukemias. (Seshacharyulu
et al., 2012; Sasaki et al., 2013; Arteaga and Engelman, 2014).
Phylogenetic analysis of the six cysteine residues distributed
throughout the EGFR catalytic domain demonstrates a strong
evolutionary conservation (Figures 1A,C). Although zebraﬁsh
share only about 40% sequence identity with human EGFR,
the catalytic domain cysteines remain conserved which sug-
gests a strong biological relevance of these residues. Of the
six residues, four (Cys781, Cys818, Cys939, and Cys950) possess
limited solvent access. Two of these four cysteines are deeply
buried in the hydrophobic pocket while the other two are at
the surface but their side chains point inward thus restrict-
ing solvent access. The remaining two residues (Cys797, Cys775)
are in close proximity to solvent channels (Figure 1B) and
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Table 1 | Protein kinases with a nucleophilic cysteine residue in the hinge region of the catalytic domain.
Kinase Biological function Disease relevance Approved and investigational
drugs
EGFR Proliferation, development and differentiation of
squamous epithelial cells, regulates cell cycle,
cytoskeletal reorganization, and cell migration
NSCLC, colorectal cancer, breast cancer,
cervical cancer, prostate cancer, renal cell
carcinoma, bladder cancer, head, and neck
cancer
Dacomitinib; Afatinib; Iressa
(Geﬁtinib); Tarceva (Erlotinib);
Erbitux (Cetuximab); Tykerb
(Lapatinib); Vectibix (Panitumumab);
Caprelsa (Vandetanib); AZD9291;
CO-1686
HER2/ErbB2 Regulates proliferation, differentiation, and
cytoskeletal rearrangement in cells, regulates
transcription and cell cycle, and cell migration
Breast cancer, glioma, ovarian cancer, lung
cancer, hereditary diffuse gastric cancer
Dacomitinib; Afatinib; Herceptin
(Trastuzumab); Kadcyla
(ado-trastuzumab emtansine);
Perjeta (Pertuzumab); Tykerb
(Lapatinib)
HER4/ErbB4 Proliferation, development, and differentiation of
cardiomyocytes; migration of neural crest cells
and mammary epithelial cells
Schizophrenia, breast cancer (tumor
suppressor), medulloblastoma, viral leukemia
Dacomitinib; Tykerb (Lapatinib)
BTK Development, proliferation, and activation of
myeloid cells, mast cells and B-cells; regulation
of apoptotic signaling; transcriptional regulation
of NF-kB
X-linked agammaglobulinemia, multiple
myeloma, non-hodgkin lymphoma,
immunodeﬁciency, wiskott-aldrich syndrome,
Ibrutinib (PCI-32765)
GDC-0834; CGI-560; HM-71224;
CC-292; ONO-4059; CNX-774;
LFM-A13
ITK Regulates T-cell signaling, trafﬁcking,
proliferation, and viral replication
Inﬂammatory skin diseases such as atopic
dermatitis, psoriasis, allergic contact dermatitis
Ibrutinib (PCI-32765)
BMX Cell differentiation, inﬂammatory signaling,
motility, survival, and angiogenesis
Hepatocellular carcinoma, prostatic
intraepithelial neoplasia, ischemia, leukemia,
lung cancer, arthritis
Ibrutinib (PCI-32765); MK2206;
Canertinib (CI-1033)
BLK Regulates B cell development, differentiation
and activation; modulates beta cell function in
pancreatic islets
Maturity-onset diabetes of the young 11
(MODY-11), motor neuropathy, scleroderma,
arthritis, lupus, acute lymphoblastic leukemia
None to date
TXK Growth, development, differentiation and
activation of T lymphocytes; actin reorganization;
regulates cytokine production in TH1 cells
Rheumatoid arthritis, Behcet’s disease,
bronchial asthma, atopic dermatitis
Ibrutinib (PCI-32765)
TEC T cell development, differentiation and cytokine
production (IL2); regulates growth and
differentiation of myeloid cells
X-linked agammaglobulinemia, autoimmune
conditions, inﬂammatory diseases, arthritis,
congenital ﬁbrosarcoma, hepatitis, squamous
cell carcinoma, lymphedema
Ibrutinib (PCI-32765)
JAK3 Cell growth, development and differentiation;
regulates hematopoiesis and gene expression
via STAT signaling
Psoriasis, rheumatoid arthritis, severe
combined immunodeﬁciency (autosomal
recessive for T− cell –ve/B cell +ve/NK cell –ve)
Tofacitinib, VX-509
MKK7 Activated in response to cellular stresses,
proinﬂammatory cytokines and regulates
apoptotic signaling in neurons. Activates
SAPK/JNK pathways in cells, regulates toll-like
receptor signaling pathways, regulates
proliferation of hematopoietic cells, regulates
differentiation of helper T cells (Th) to Th1
Advanced stage prostatic tumors,
schizophrenia,
hypertrophic cardiac diseases (animal
models)
None to date
Redox modiﬁcations have been reported for a subset of these proteins (e.g., EGFR, BTK, JAK3).
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FIGURE 1 | Pharmacological role of evolutionarily conserved
EGFR-Cys797. (A) Catalytic domain ofWT EGFR depicting all six cysteine
residues. (B) Surface structure ofWT EGFR shows Cys775 and Cys797 as the
two solvent-accessible cysteine residues (PDB 1M14). (C) Schematic
representation of EGFR domains: ligand binding extracellular domain (blue),
the transmembrane domain (green), juxtamembrane region, JM (white) and
the catalytic domain (red). Phylogenetic analysis of catalytic domain cysteine
residues for the indicated species using the Uniprot Clustal O sequence
alignment tool. Solvent-exposed cysteine residues are in red font. (D) Binding
of small molecule inhibitors to theWT EGFR active site is shown in context of
Cys797 (yellow; PDB 1M17). Reversible inhibitor erlotinib (green) binding to
WT EGFR (left), covalent inhibitor dacomitinib (purple) binding to the reduced
thiol Cys797−SH ofWT EGFR (middle) and the sulﬁnylated Cys797−SO2 WT
EGFR (right).
are likely to undergo redox modiﬁcations. Historically, one of
these solvent-exposed cysteines has been targeted for therapeutic
intervention (Cys797).
Covalent kinase inhibition is a well-known pharmacologi-
cal strategy that targets non-catalytic nucleophilic residues (e.g.,
Cys797 of EGFR) with electrophilic inhibitors. This approach was
pursued to create highly potent drugs with prolonged pharmaco-
logical effects and enhanced selectivity (Singh et al., 1997; Schwartz
et al., 2014). The most prevalent approach uses a Michael addition
reaction of a nucleophilic cysteine thiol with the electron-deﬁcient
β-carbon of the Michael acceptor (MA) substituent of a cova-
lent inhibitor. Several FDA-approved covalent drugs utilize this
approach (e.g., afatinib, ibrutinib; Table 1). EGFR-Cys797 is capa-
ble of undergoing multiple redox modiﬁcations (sulﬁnylation and
glutathionylation) that can impact the potency of targeted drugs
(Schwartz et al., 2014). Our studies show that reversible binding
afﬁnity of EGFR inhibitors is highly variable dependent on the
inhibitor structure, the type of redox modiﬁcation of Cys797, and
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the protein context (type of mutation). For example, biochemical
afﬁnity of the covalent inhibitor dacomitinib decreased by about
30-fold when the L858R EGFR mutant was glutathionylated (K i
from 0.7 to 21 nM) but was unaffected by sulﬁnylation (K i from
0.7 to 1.0 nM). A similar trend was observed with the drug-
resistant L858R/T790MEGFRmutant, however, the loss in afﬁnity
was more substantial for the glutathionylated protein (>50-fold).
The active sites of WT and L858R mutant EGFR are structurally
very similar, hence biochemical afﬁnities of their covalent drugs
are expected to be comparable. Modeling studies of dacomi-
tinib interactions with WT EGFR and WT EGFR sulﬁnylated
at Cys797 do not predict signiﬁcant loss of interactions between
the inhibitor MA and sulﬁnylated EGFR-Cys797 which is consis-
tent with the modest decrease in afﬁnities (Figure 1D). However,
the more substantial loss of dacomitinib interactions with glu-
tathionylated EGFR-Cys797 may occur due to reduced access of
the inhibitor to the ATP-binding pocket therefore interfering with
both covalent and non-covalent interactions. For non-covalent
drugs such as erlotinib that do not require EGFR-Cys797 interac-
tions, the loss of afﬁnity was modest for the both EGFR mutants
(about twofold). As such, redox modiﬁcations of protein kinases
can result in a wide range of pharmacological effects and be
inhibitor-speciﬁc.
In cellular environments, the pharmacology of covalent
inhibitors can be more complex due to spatially distinct and
temporally controlled redox signaling mechanisms. The rate of
formation and stability of oxidized-EGFR can vary depending
on the local redox environment within subcellular compart-
ments. Therefore, an inhibitormayhave different interactions (i.e.,
potency) with a given protein based on its subcellular location. As
such, two EGFR inhibitors may have a different spectrum of pharma-
cological effects due to their individual abilities to bind to different
redox forms of EGFR. This new frontier of drug pharmacology
should be exploited to create more effective and better-tolerated
drugs.
SUMMARY
Despite their lowabundance in themammalianproteome, cysteine
residues have emerged as important effectors of signaling regula-
tion in both healthy cells and pathophysiological states. The chem-
istry of cysteine residues enables many types of post-translational
oxidation reactions in cells with unique roles relative to the other
amino acids. The conformational changes induced by redox mod-
iﬁcations in signaling proteins can regulate biological outcomes.
The spatial networks created by compartmentalized trafﬁcking of
redox-active proteins between distinct redox microenvironments
impart selectivity to the kinase signaling. Temporal separation
of the localized redox networks further reﬁnes signaling regula-
tion. Speciﬁc cysteine oxidation events can also modulate small
molecule inhibitor interactions and impact the clinical perfor-
mance of these drugs. As such, redox analysis is necessary to gain
a deeper understanding of biology and to design more effective
drugs.
AUTHOR CONTRIBUTIONS
Both authors contributed to this work and approve the version to
be published and are also accountable for all aspects of the work.
ACKNOWLEDGMENTS
We would like to acknowledge the Pﬁzer postdoctoral program
for funding Revati Wani We would like to acknowledge the con-
tribution of all the studies that allowed us to develop the concept
in this manuscript, however, could not be cited owing to space
limitations.
REFERENCES
Arteaga, C. L., andEngelman, J.A. (2014). ERBB receptors: fromoncogene discovery
to basic science to mechanism-Based cancer therapeutics. Cancer Cell 25, 282–
303. doi: 10.1016/j.ccr.2014.02.025
Bae, Y. S., Kang, S. W., Seo, M. S., Baines, I. C., Tekle, E., Chock, P. B., et al. (1997).
Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role
in EGF receptor-mediated tyrosine phosphorylation. J. Biol. Chem. 272, 217–221.
doi: 10.1074/jbc.272.1.217
Bindoli, A., Fukuto, J. M., and Forman, H. J. (2008). Thiol chemistry in peroxi-
dase catalysis and redox signaling. Antioxid. Redox Signal. 10, 1549–1564. doi:
10.1089/ars.2008.2063
Bindoli, A., and Rigobello, M. P. (2013). Principles in redox signaling: from chem-
istry to functional signiﬁcance. Antioxid. Redox Signal. 18, 1557–1593. doi:
10.1089/ars.2012.4655
Bourles, E., Isaac, M., Lebrun, C., Latour, J. M., and Seneque, O. (2011). Oxidation
of Zn(Cys)4 zinc ﬁnger peptides by O2 and H2O2: products, mechanism and
kinetics. Chemistry 17, 13762–13772. doi: 10.1002/chem.201101913
Brandes, N., Schmitt, S., and Jakob, U. (2009). Thiol-based redox switches in
eukaryotic proteins. Antioxid. Redox Signal. 11, 997–1014. doi: 10.1089/ARS.200
8.2285
Carpenter, G., and Liao, H. J. (2009). Trafﬁcking of receptor tyrosine kinases to the
nucleus. Exp. Cell Res. 315, 1556–1566. doi: 10.1016/j.yexcr.2008.09.027
Chen, K., Kirber, M. T., Xiao, H., Yang, Y., and Keaney, J. F. Jr. (2008). Regulation
of ROS signal transduction by NADPH oxidase 4 localization. J. Cell. Biol. 181,
1129–1139. doi: 10.1083/jcb.200709049
Chigaev, A., Zwartz, G. J., Buranda, T., Edwards, B. S., Prossnitz, E. R., and
Sklar, L. A. (2004). Conformational regulation of alpha 4 beta 1-integrin afﬁn-
ity by reducing agents. “Inside-out” signaling is independent of and additive to
reduction-regulated integrin activation. J. Biol. Chem. 279, 32435–32443. doi:
10.1074/jbc.M404387200
Corcoran, A., and Cotter, T. G. (2013). Redox regulation of protein kinases. FEBS J.
280, 1944–1965. doi: 10.1111/febs.12224
Cremers, C. M., and Jakob, U. (2013). Oxidant sensing by reversible disulﬁde bond
formation. J. Biol. Chem. 288, 26489–26496. doi: 10.1074/jbc.R113.462929
Cross, J. V., and Templeton, D. J. (2006). Regulation of signal transduction
through protein cysteine oxidation. Antioxid. Redox Signal. 8, 1819–1827. doi:
10.1089/ars.2006.8.1819
D’Autreaux, B., and Toledano, M. B. (2007). ROS as signalling molecules: mecha-
nisms that generate speciﬁcity in ROS homeostasis. Nat. Rev. Mol. Cell Biol. 8,
813–824. doi: 10.1038/nrm2256
Diao, Y., Liu, W., Wong, C. C. L., Wang, X., Lee, K., Cheung, P.-Y., et al. (2010).
Oxidation-induced intramolecular disulﬁde bond inactivates mitogen-activated
protein kinase kinase 6 by inhibiting ATP binding. Proc. Natl. Acad. Sci. U.S.A.
107, 20974–20979. doi: 10.1073/pnas.1007225107
Dickinson, B. C., and Chang, C. J. (2011). Chemistry and biology of reactive oxy-
gen species in signaling or stress responses. Nat. Chem. Biol. 7, 504–511. doi:
10.1038/nchembio.607
Drose, S., and Brandt, U. (2012). Molecular mechanisms of superoxide production
by the mitochondrial respiratory chain. Adv. Exp. Med. Biol. 748, 145–169. doi:
10.1007/978-1-4614-3573-0_6
El Hajjaji, H., Dumoulin, M., Matagne, A., Colau, D., Roos, G., Messens,
J., et al. (2009). The zinc center inﬂuences the redox and thermodynamic
properties of Escherichia coli thioredoxin 2. J. Mol. Biol. 386, 60–71. doi:
10.1016/j.jmb.2008.11.046
Fan, S. W., George, R. A., Haworth, N. L., Feng, L. L., Liu, J. Y., and Wouters, M. A.
(2009). Conformational changes in redox pairs of protein structures. Protein Sci.
18, 1745–1765. doi: 10.1002/pro.175
Farah, M. E., Sirotkin, V., Haarer, B., Kakhniashvili, D., and Amberg, D. C.
(2011). Diverse protective roles of the actin cytoskeleton during oxidative stress.
Cytoskeleton 68, 340–354. doi: 10.1002/cm.20516
Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs October 2014 | Volume 5 | Article 224 | 6
Wani et al. Redox mediated signaling and pharmacology
Foley, T. D., Petro, L. A., Stredny, C. M., and Coppa, T. M. (2007). Oxidative
inhibition of protein phosphatase 2A activity: role of catalytic subunit disulﬁdes.
Neurochem. Res. 32, 1957–1964. doi: 10.1007/s11064-007-9394-x
García-Yagüe, Á. J., Rada, P., Rojo, A. I., Lastres-Becker, I., and Cuadrado, A.
(2013). Nuclear import and export signals control the subcellular localization of
Nurr1 protein in response to oxidative stress. J. Biol. Chem. 288, 5506–5517. doi:
10.1074/jbc.M112.439190
Giannoni, E., Buricchi, F., Raugei, G., Ramponi, G., and Chiarugi, P. (2005).
Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhe-
sion and anchorage-dependent cell growth. Mol. Cell. Biol. 25, 6391–6403. doi:
10.1128/mcb.25.15.6391-6403.2005
Gopalakrishna, R., and Jaken, S. (2000). Protein kinase C signaling and oxida-
tive stress. Free Radic. Biol. Med. 28, 1349–1361. doi: 10.1016/S0891-5849(00)0
0221-5
Heo, L., Cho, Y. B., Lee, M. S., Roe, J. H., and Seok, C. (2013). Alternative zinc-
binding sites explain the redox sensitivity of zinc-containing anti-sigma factors.
Proteins 81, 1644–1652. doi: 10.1002/prot.24323
Ilbert, M., Graf, P. C., and Jakob, U. (2006). Zinc center as redox switch–new
function for an oldmotif. Antioxid. Redox Signal. 8, 835–846. doi: 10.1089/ars.200
6.8.835
Jacob, C., Battaglia, E., Burkholz, T., Peng, D., Bagrel, D., and Montenarh, M.
(2011). Control of oxidative posttranslational cysteine modiﬁcations: from intri-
cate chemistry to widespread biological and medical applications. Chem. Res.
Toxicol. 25, 588–604. doi: 10.1021/tx200342b
Khan, E. M., Heidinger, J. M., Levy, M., Lisanti, M. P., Ravid, T., and Goldkorn, T.
(2006). Epidermal growth factor receptor exposed to oxidative stress undergoes
Src- and caveolin-1-dependent perinuclear trafﬁcking. J. Biol. Chem. 281, 14486–
14493. doi: 10.1074/jbc.M509332200
Kitagishi, Y., and Matsuda, S. (2013). Redox regulation of tumor suppressor
PTEN in cancer and aging (Review). Int. J. Mol. Med. 31, 511–515. doi:
10.3892/ijmm.2013.1235
Korichneva, I. (2005). Redox regulation of cardiac protein kinase C. Exp. Clin.
Cardiol. 10, 256–261.
Kwon, J., Lee, S.-R., Yang, K.-S., Ahn, Y., Kim, Y. J., Stadtman, E. R., et al. (2004).
Reversible oxidation and inactivation of the tumor suppressor PTEN in cells
stimulated with peptide growth factors. Proc. Natl. Acad. Sci. U.S.A. 101, 16419–
16424. doi: 10.1073/pnas.0407396101
Landino, L. M., Koumas, M. T., Mason, C. E., and Alston, J. A. (2007).
Modiﬁcation of tubulin cysteines by nitric oxide and nitroxyl donors alters
tubulin polymerization activity†. Chem. Res. Toxicol. 20, 1693–1700. doi:
10.1021/tx7001492
Layani-Bazar, A., Skornick, I., Berrebi, A., Pauker, M. H., Noy, E., Silberman, A.,
et al. (2014). Redox modulation of adjacent thiols in VLA-4 by AS101 converts
myeloid leukemia cells from a drug-resistant to drug-sensitive state. Cancer Res.
74, 3092–3103. doi: 10.1158/0008-5472.CAN-13-2159
Lu, L., Sun, X., Liu, Y., Zhao, H., Zhao, S., and Yang, H. (2012). DJ-1 upregu-
lates tyrosine hydroxylase gene expression by activating its transcriptional factor
Nurr1 via the ERK1/2 pathway. Int. J. Biochem. Cell Biol. 44, 65–71. doi:
10.1016/j.biocel.2011.09.007
Marinho, H. S., Real, C., Cyrne, L., Soares, H., and Antunes, F. (2014). Hydrogen
peroxide sensing, signaling and regulation of transcription factors. Redox Biol. 2,
535–562. doi: 10.1016/j.redox.2014.02.006
Miseta, A., and Csutora, P. (2000). Relationship between the occurrence of cysteine
in proteins and the complexity of organisms. Mol. Biol. Evol. 17, 1232–1239. doi:
10.1093/oxfordjournals.molbev.a026406
Moskovitz, J. (2005). Methionine sulfoxide reductases: ubiquitous enzymes involved
in antioxidant defense, protein regulation, and prevention of aging-associated
diseases. Biochim. Biophys. Acta 1703, 213–219. doi: 10.1016/j.bbapap.2004.
09.003
Moskovitz, J., Maiti, P., Lopes, D. H., Oien, D. B., Attar, A., Liu, T., et al. (2011).
Induction of methionine-sulfoxide reductases protects neurons from amyloid
beta-protein insults in vitro and in vivo. Biochemistry 50, 10687–10697. doi:
10.1021/bi201426b
Murphy, J. E., Padilla, B. E., Hasdemir, B., Cottrell, G. S., and Bunnett, N. W. (2009).
Endosomes: a legitimate platform for the signaling train. Proc. Natl. Acad. Sci.
U.S.A. 106, 17615–17622. doi: 10.1073/pnas.0906541106
Östman, A., Frijhoff, J., Sandin, Å., and Böhmer, F.-D. (2011). Regulation of protein
tyrosine phosphatases by reversible oxidation. J. Biochem. 150, 345–356. doi:
10.1093/jb/mvr104
Oteiza, P. I. (2012). Zinc and the modulation of redox homeostasis. Free Radic. Biol.
Med. 53, 1748–1759. doi: 10.1016/j.freeradbiomed.2012.08.568
O-Uchi, J., Ryu, S. Y., Jhun, B. S., Hurst, S., and Sheu, S. S. (2014). Mitochondrial
ion channels/transporters as sensors and regulators of cellular redox signaling.
Antioxid. Redox Signal. 21, 987–1006. doi: 10.1089/ars.2013.5681
PaigeDavisVolk,A., andMoreland, J.G. (2014).“Chapter thirteen–ROS-containing
endosomal compartments: implications for signaling,” in Methods in Enzymology,
ed. P. M. Conn (Iowa, IA: Academic Press), 201–224.
Parsons, Z. D., andGates, K. S. (2013). Thiol-dependent recovery of catalytic activity
from oxidized protein tyrosine phosphatases. Biochemistry 52, 6412–6423. doi:
10.1021/bi400451m
Paulsen, C. E., Truong, T.H., Garcia, F. J., Homann,A., Gupta,V., Leonard,S. E., et al.
(2012). Peroxide-dependent sulfenylation of the EGFR catalytic site enhances
kinase activity. Nat. Chem. Biol. 8, 57–64. doi: 10.1038/nchembio.736
Pizarro, G. O., and Ogut, O. (2009). Impact of actin glutathionylation on the
actomyosin-S1 ATPase. Biochemistry 48, 7533–7538. doi: 10.1021/bi900669m
Rao, R., Xu, D., Thelen, J., and Miernyk, J. (2013). Circles within circles:
crosstalk between protein Ser/Thr/Tyr-phosphorylation and Met oxidation. BMC
Bioinformatics 14:S14. doi: 10.1186/1471-2105-14-S14-S14
Ringman, J. M., Fithian, A. T., Gylys, K., Cummings, J. L., Coppola, G.,
Elashoff, D., et al. (2012). Plasma methionine sulfoxide in persons with famil-
ial Alzheimer’s disease mutations. Dement. Geriatr. Cogn. Disord. 33, 219–225.
doi: 10.1159/000338546000338546
Roos, G., Foloppe, N., and Messens, J. (2013). Understanding the pK(a) of redox
cysteines: the key role of hydrogen bonding. Antioxid. Redox Signal. 18, 94–127.
doi: 10.1089/ars.2012.4521
Sasaki, T., Hiroki, K., and Yamashita, Y. (2013). The role of epidermal growth factor
receptor in cancer metastasis and microenvironment. Biomed. Res. Int. 2013,
546318. doi: 10.1155/2013/546318
Schoneich, C. (2005). Methionine oxidation by reactive oxygen species: reaction
mechanisms and relevance to Alzheimer’s disease. Biochim. Biophys. Acta 1703,
111–119. doi: 10.1016/j.bbapap.2004.09.009
Schoneich, C. (2011). Cysteine residues as catalysts for covalent peptide and protein
modiﬁcation: a role for thiyl radicals? Biochem. Soc. Trans. 39, 1254–1259. doi:
10.1042/bst0391254
Schwartz, P. A., Kuzmic, P., Solowiej, J., Bergqvist, S., Bolanos, B., Almaden, C.,
et al. (2014). Covalent EGFR inhibitor analysis reveals importance of reversible
interactions to potency and mechanisms of drug resistance. Proc. Natl. Acad. Sci.
U.S.A. 111, 173–178. doi: 10.1073/pnas.1313733111
Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., and
Batra, S. K. (2012). Targeting the EGFR signaling pathway in cancer therapy.
Expert Opin. Ther. Targets 16, 15–31. doi: 10.1517/14728222.2011.648617
Singh, J., Dobrusin, E. M., Fry, D. W., Haske, T., Whitty, A., and Mcnamara, D. J.
(1997). Structure-based design of a potent, selective, and irreversible inhibitor of
the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
J. Med. Chem. 40, 1130–1135. doi: 10.1021/jm960380s
Sorkin,A., and Goh, L. K. (2009). Endocytosis and intracellular trafﬁcking of ErbBs.
Exp. Cell Res. 315, 683–696. doi: 10.1016/j.yexcr.2008.07.029
Steinberg, S. F. (2013). Oxidative stress and sarcomeric proteins. Circ. Res. 112,
393–405. doi: 10.1161/circresaha.111.300496
Surh, Y. J., Kundu, J. K., Na, H. K., and Lee, J. S. (2005). Redox-sensitive transcrip-
tion factors as prime targets for chemoprevention with anti-inﬂammatory and
antioxidative phytochemicals. J. Nutr. 135, 2993S–3001S.
Tomas, A., Futter, C. E., and Eden, E. R. (2014). EGF receptor trafﬁcking:
consequences for signaling and cancer. Trends Cell Biol. 24, 26–34. doi:
10.1016/j.tcb.2013.11.002
Wang, Y., Yang, J., and Yi, J. (2012). Redox sensing by proteins: oxidative modiﬁca-
tions on cysteines and the consequent events. Antioxid. Redox Signal. 16, 649–657.
doi: 10.1089/ars.2011.4313
Wani, R., Qian, J.,Yin, L., Bechtold, E., King, S. B., Poole, L. B., et al. (2011). Isoform-
speciﬁc regulation of Akt by PDGF-induced reactive oxygen species. Proc. Natl.
Acad. Sci. U.S.A. 108, 10550–10555. doi: 10.1073/pnas.1011665108
Winterbourn,C.C. (2008). Reconciling the chemistry andbiology of reactive oxygen
species. Nat. Chem. Biol. 4, 278–286. doi: 10.1038/nchembio.85
Wouters, M. A., Fan, S. W., and Haworth, N. L. (2010). Disulﬁdes as redox switches:
from molecular mechanisms to functional signiﬁcance. Antioxid. Redox Signal.
12, 53–91. doi: 10.1089/ARS.2009.2510
Yan, B., and Smith, J. W. (2000). A redox site involved in integrin activation. J. Biol.
Chem. 275, 39964–39972. doi: 10.1074/jbc.M007041200
www.frontiersin.org October 2014 | Volume 5 | Article 224 | 7
Wani et al. Redox mediated signaling and pharmacology
Yan, B., and Smith, J. W. (2001). Mechanism of integrin activation by disulﬁde bond
reduction. Biochemistry 40, 8861–8867. doi: 10.1021/bi002902i
Zhao, F., Ilbert, M., Varadan, R., Cremers, C. M., Hoyos, B., Acin-Perez, R., et al.
(2011). Are zinc-ﬁnger domains of protein kinase C dynamic structures that
unfold by lipid or redox activation? Antioxid. Redox Signal. 14, 757–766. doi:
10.1089/ars.2010.3773
Zhong, X., and Wright, J. F. (2013). Biological insights into therapeutic protein
modiﬁcations throughout trafﬁcking and their biopharmaceutical applications.
Int. J. Cell. Biol. 2013:273086. doi: 10.1155/2013/273086
Conflict of Interest Statement:The authors declare that the researchwas conducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 08 July 2014; accepted: 17 September 2014; published online: 06 October
2014.
Citation: Wani R, Nagata A and Murray BW (2014) Protein redox chemistry:
post-translational cysteine modiﬁcations that regulate signal transduction and drug
pharmacology. Front. Pharmacol. 5:224. doi: 10.3389/fphar.2014.00224
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the
journal Frontiers in Pharmacology.
Copyright © 2014Wani, Nagata and Murray. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs October 2014 | Volume 5 | Article 224 | 8
